Immunicon Corporation to Introduce Repeat-Free(TM) Poseidon(TM) FISH Probes And Present Workshop and Posters at 2008 AACR Annual
09 April 2008 - 9:00PM
Business Wire
Immunicon Corporation (NASDAQ-GM:IMMC) will introduce its portfolio
of Repeat-Free� Poseidon� FISH probes at the Annual Meeting of the
American Association for Cancer Research (AACR), the premier
educational and scientific event in the oncology research
community, April 12-16 at the San Diego Convention Center, San
Diego California. In addition, Immunicon will participate in a
workshop on circulating tumor cells and present two posters on two
new rare cell detection kits based on CellTracks� technology,
circulating endothelial cell subsets and circulating melanoma
cells. Immunicon will exhibit the Repeat-Free� Poseidon� FISH
probes and the CellCapture� CTC Mouse/Rat Kit at booth number 2029.
Immunicon believes that Repeat-Free� technology eliminates the need
to use blocking reagents and that RF Poseidon Probes reduces
background and provide brighter signals. Most importantly, RF
Poseidon Probes need only 4 hours of hybridization time to reach
full signal strength, compared to 16 hour hybridization time for
traditional probes. Immunicon believes that this workflow
improvement combined with assay performance represents clear
competitive advantages in the field. The CellCapture� CTC Mouse/Rat
Kit enables pre-clinical studies using circulating tumor cells
(CTCs) in animal models. The CellCapture� Kit uses a manual test
procedure to capture CTCs in a few drops of mouse blood and the
cells are counted and characterized using the CellTracks� Analyzer
II. This kit will enable scientists to conduct efficacy studies in
very early drug studies and may streamline this important phase of
drug development. The CellCapture� CTC Mouse Kit and CellTracks�
Analyzer II are sold by the Immunicon sales team directly.
Workshop: Circulating Tumor Cells Saturday, 1:00 PM-3:00 PM, Room
30A-C, San Diego Convention Center 1:40 PM � Monitoring and
characterization of CTC in cancer patients � Leon W.M.M.
Terstappen, Immunicon Corporation, Huntingdon Valley, PA � Poster
Presentations Sunday, April 13 1:00-5:00 PM Poster Section 12,
Abstract #1083, Board 14 Enumeration of VEGFR2 and Ki67 positive
subsets of circulating endothelial cells in blood Chandra Rao, Yao
Yao, Mark Connelly, Mark Middleton, Gerald Doyle, Leon Terstappen.
� Monday, April 14 8:00 AM-12:00 Poster Section 24, Abstract #2174,
Board 19 Cytogenetic analysis of Circulating Tumor Cells of
metastatic prostate cancer Arjan Gj Tibbe, Joost F. Swenenhuis,
Rianne Levink, Ronald CJ Sipkema, Leon WMM Terstappen. � Tuesday,
April 15 8:00 AM-12:00 Poster Section 12, Abstract #3695, Board 24
Automated enumeration and characterization of circulating melanoma
cells in blood Chandra Rao, Thai Bui, Mark Connelly, Mark
Middleton, Gerald Doyle, Leon Terstappen. � Tuesday, April 15 8:00
AM-12:00 Poster Section 12, Abstract #3693, Board 22 Dynamics of
circulating tumor cells in mice bearing human breast cancer
xenografts Jean-Pierre Eliane, Madeline Repollet, Kathryn E. Luker,
Martha Brown, James E. Rae, Gerald V. Doyle, Daniel F. Hayes, Gary
D. Luker. Following the conference, the Immunicon presentations
will be posted on Immunicon�s Web site at http://www.immunicon.com.
For more about the 2008 AACR Annual Meeting, visit
http://www.aacr.org/. About Immunicon Corporation Immunicon
Corporation is developing and commercializing proprietary cell- and
molecular-based human diagnostic and life science research
products, and is providing certain analytical services to
pharmaceutical and biotechnology companies to assist them in
developing new therapeutic agents, with an initial focus on cancer
disease management. Immunicon has developed platform technologies
to identify, count and characterize a small number of rare cells in
blood, such as circulating tumor cells and circulating endothelial
cells that are important in many diseases and biological processes.
Immunicon�s products and underlying technology platforms also have
application in cancer research and may have applications in other
fields of medicine, such as cardiovascular and infectious diseases.
For more information, please visit www.immunicon.com.
Forward-Looking Statements This press release may contain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are often preceded by words such as �hope,� �may,�
�believe,� �anticipate,� �plan,� �expect,� �intend,� �assume,�
�will� and similar expressions. Forward-looking statements
contained in this press release include, among others, statements
regarding the anticipated clinical utility of Immunicon�s products
and other statements not of historical fact. Immunicon cautions
investors not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release,
are based on the current expectations and intent of the management
of Immunicon and involve certain factors, such as risks and
uncertainties that may cause actual results to be far different
from those suggested by these statements. These statements are not
guarantees of future performance and involve risks and
uncertainties that are difficult to predict, including, but not
limited to, risks and uncertainties associated with: Immunicon�s
ability to continue as a going concern; Immunicon�s dependence on
Veridex, LLC, a Johnson & Johnson company; the risks and
uncertainties with the arbitration proceeding with Veridex and the
award in favor of Veridex given Immunicon�s dependencies on
Veridex; the ability to earn license and milestone payments under
Immunicon�s agreement with Veridex; Immunicon�s capital and
financing needs; research and development and clinical trial
expenditures; commercialization of product candidates; Immunicon�s
ability to obtain licenses from third parties to commercialize
products; Immunicon�s ability to manage its growth; obtaining
necessary regulatory approvals; reliance on third party
manufacturers and suppliers; reimbursement by third party payors to
Immunicon�s customers; compliance with applicable manufacturing
standards; retaining key personnel; delays in the development of
new products or planned improvements to products; effectiveness of
products compared to competitors� products; protection of
Immunicon�s intellectual property; conflicts with third party
intellectual property; product liability lawsuits that may be
brought against Immunicon; labor, contract or technical
difficulties; and competitive pressures in Immunicon�s industry.
These factors are discussed in more detail in Immunicon�s filings
with the Securities and Exchange Commission. Except as required by
law, Immunicon accepts no responsibility for updating the
information contained in this press release beyond the published
date, whether as a result of new information, future events or
otherwise, or for modifications made to this document by Internet
or wire services. �Immunicon,� �CellTracks� and the Immunicon
Corporation logo are registered trademarks of Immunivest
Corporation, a subsidiary of Immunicon Corporation. Repeat-Free is
a trademark of Immunivest Corporation. Poseidon is a trademark of
Kreatech Diagnostics. ALL RIGHTS RESERVED.
Immunicon (NASDAQ:IMMC)
Historical Stock Chart
From May 2024 to Jun 2024
Immunicon (NASDAQ:IMMC)
Historical Stock Chart
From Jun 2023 to Jun 2024